Abstract This study was carried out to investigate the activation status of unfolded protein response (UPR) in colorectal cancer (CRC) and its contribution to CRC resistance to chemotherapy-induced apoptosis. Chemotherapy-induced apoptosis was assessed by the propidium iodide method. Activation of UPR was evaluated in CRC cell lines using immunoblotting technique and in CRC tissues using immunohistochemistry. Findings of the present study revealed that the UPR is constitutively activated in CRC cell lines and CRC tissues isolated from patients, as evidenced by relatively high levels of the 78-kDa glucoseregulated protein (GRP78) and spliced X-box-binding protein 1 mRNA in tissue samples. In addition, CRC cell lines differentially responded to clinically relevant DNA-targeting agents including cisplatin, and 5-flourouracil. Moreover, the levels of GRP78 were inversely associated with sensitivity of CRC cells to chemotherapy-induced apoptosis. Inhibition of GRP78 by siRNA resulted in increased sensitivity of CRC cells to chemotherapeutic agents. Collectively, current results appear to provide novel insights into the role of UPR in determining sensitivity of CRC cells to chemotherapeutic agents and might have important implications for personalized CRC treatment.
Introduction
Cellular conditions such as hypoxia, alterations in glycosylation status, and disturbances of calcium flux, can lead to the accumulation of unfolded and/or misfolded proteins in the endoplasmic reticulum (ER) lumen and can challenge the function of the ER-Golgi network, resulting ER stress (Harding et al. 2002; Zhang and Kaufman 2004; Schroder and Kaufman 2005) . The ER responds to stress conditions by unfolded protein response (UPR), which involves activation of a range of signaling pathways that couple ER protein folding load with ER protein folding capacity (Harding et al. 2002; Zhang and Kaufman 2004; Schroder and Kaufman 2005) .
The UPR is of fundamental importance for survival of all eukaryotic cells under conditions of ER stress.
The response is mediated by sequestration of the 78-kDa glucose regulated protein (GRP78) by unfolded proteins, which activates three ER transmembrane protein sensors: activating transcription factor 6 (ATF6), inositol-requiring enzyme 1 (IRE1) and double stranded RNA-activated protein kinaselike ER kinase (PERK) (Harding et al. 2002; Zhang and Kaufman 2004; Schroder and Kaufman 2005) . These activations involve phosphorylation and homodimerization of IRE1 and PERK, and relocation and proteolytic cleavage of ATF6 (Harding et al. 2002; Zhang and Kaufman 2004; Schroder and Kaufman 2005) .
In addition to the UPR sensing, GRP78 protein acts as ER chaperone that facilitates proper protein folding and targets misfolded proteins for degradation by proteasome. It is also involved in ER calcium binding. Elevated expression of GRP78 has been reported in several cancers, such as breast cancer and prostate cancer (Erhardt et al. 1999; Adeyinka et al. 2002) . Moreover, GRP78 expression has been associated with tumor development and growth, vascularization, metastasis and correlated with cancer resistance to chemotherapy (Erhardt et al. 1999; Reddy et al. 2003; Pyrko et al. 2007) . It seems that some cancer cells may have adapted to ER stress by activation of the UPR without resulting in apoptosis (Rutkowski et al. 2006; Rutkowski and Kaufman 2007) . It has been suggested that the central feature of this adaptive response is the maintenance of the expression of proteins that facilitate survival, such as GRP78 (Rutkowski et al. 2006) .
Colorectal cancer (CRC) is common among adult men and women. Despite the progress in treatment of CRC, millions of patients die due to development of resistance of malignant cells to therapy (Fang 2009; Gottschalk et al. 2010) . Although several experimental studies have explored the role of GRP78 in colorectal cancer growth, progression and apoptosis (Takahashi et al. 2011; Xing et al. 2011) , it is unclear whether there is an association between the expression levels of GRP78 and CRC response to DNAtargeting agents such as cisplatin. In the present study, results indicated that GRP78 is constitutively activated in cultured CRC cell lines and CRC tissues, and plays a profound role in regulating sensitivity of CRC cells to apoptosis induced by chemotherapy. It is likely that pretreatment evaluation of the expression of GRP78 will be a useful biomarker for response of CRC patient's to DNA-targeting agents and to establish a baseline for personalized treatment of CRC patients.
Materials and methods

Cell lines
Human CRC cell lines (Colo205, SW480, SW620, and HCT116), and normal fibroblasts that originated from spleen tissues, were generously provided by Dr. Rick F. Thorne (University of Newcastle, Callaghan NSW, Australia) and were cultured in DMEM containing 10 % fetal calf serum (Bio Whittaker, Verviers, Belgium).
Chemicals and reagents
Chemotherapeutic agents, cisplatin and 5-flourouracil (5-FU), were purchased from Sigma-Aldrich (St. Louis, MO, USA) and stored as a 20 mM stock solution in dimethyl sulfoxide (final concentration of 0.1 % (v/v), which was shown not to contribute to cytotoxicity (Galvao et al. 2014) , at -80°C. This stock solution was diluted with the DMEM medium (containing 10 % FBS) prior to use. The propidium iodide (PI) was purchased from Sigma-Aldrich (Sigma-Aldrich). The rabbit MAbs' against GRP78/ Bip, eukaryotic initiation factor 2a (eIF2a), phosphorylated eIF2a, X-box-binding protein 1 (XBP1), IRE1a, ATF6, PERK were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Apoptosis
Apoptotic cells were determined by the propidium iodide method (Mhaidat et al. 2007 ). In brief, CRC cells were adhered overnight in a 24-well plate at a concentration of 1 9 10 5 /well in 10 % FCS. Cells in suspension were added on the day of the assay. Medium was removed, and 1,000 ll of fresh medium and 10 % FCS containing 5-FU at 50 lM or cisplatin at 166.7 lM were added. Then, Cells were incubated for 72 h at 37°C, and followed by medium removal. Adhered and suspended cells were washed once with PBS. The medium and PBS were placed in 12 9 75 mm Falcon polystyrene tubes and centrifuged at 2009g for 5 min. A hypotonic buffer 1 ml (propidium iodide, 50 lg/ml, in 0.1 % sodium citrate plus 0.1 % Triton X-100; Sigma) was added directly to the cells adherent in the 24-well plate and gently pipetted off, then, added to the appropriate cell pellet in the Falcon tube. The tubes were placed at 4°C in the dark overnight before flow cytometric analyses. The propidium iodide fluorescence of individual nucleus was measured in the red fluorescene using a Facscan flow cytometer (Becton-Dickinson, Mountain View, CA, USA) and the data were registered in a logarithmic scale. At least 10 4 cells of each sample were analyzed. Apoptotic nuclei appeared as a broad hypodiploid DNA peak, which was easily distinguished from the narrow hyperdiploid peak of nuclei in the CRC cells.
Protein expression analysis
Cell extracts were prepared as described previously (Mhaidat et al. 2012 ) and the protein content was determined by the Bradford assay (Bio-Rad, Hercules, CA, USA). Briefly, a total of 30 lg of total protein was added to each well of 12 % SDS-PAGE gels. Electrophoresis was carried out. Then, proteins on the gels were transferred onto nitrocellulose membranes. Membranes were blocked using 5 % skim milk before overnight incubation with the primary antibodies at a concentration of 1:100 v/v. Incubation of membranes with horseradish peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (1:2,000 v/v; Bio-Rad) was performed at room temperature with shaking for 1 h. Labeled bands were detected with Immuno-Star HRP Chemiluminescent Kit and the images were captured using the VersaDoc image system (Bio-Rad). The intensity of the bands was quantified with the Bio-Rad VersaDocTM image system. The relative expression of detected proteins was determined as shown previously (Mhaidat et al. 2008) . Briefly, the relative expression of GRP78 was determined by dividing the densitometric value of the test protein by that of the GAPDH.
Small RNA interference (siRNA)
The siRNA constructs were obtained as the siGE-NOME SMARTpool reagents (Dharmacon, Lafayette, CO, USA). siRNAs were transfected with Dharma-FECT I (Dharmacon) using the manufacturers' protocols. The sequences of the siRNAs are as follows: control nontargeting siRNA (D-001220-01-05) and GRP78 (L-008198-00-0005). Transfection of siRNA pools was carried out as described previously (Mhaidat et al. 2007) . Briefly, cells were transfected with 100 nM siRNA in Opti-MEM medium (Invitrogen, Carlsbad, CA, USA) with 5 % fetal calf serum using DharmaFECT I according to the manufacturer's transfection protocol. Twenty-four hours after transfection, cells were switched into medium containing 5 % FCS with or without treatment of cisplatin at 166.7 lM or 5-FU at 50 lM. After 72 h, apoptotic cells were quantified of by measurement of sub-G1 DNA content using the PI method in flow cytometry. Efficiency of siRNA was measured by Western blot analysis.
Detection of XBP1 mRNA splicing
The method used for detection of unspliced and spliced XBP1 mRNAs was as described previously . Briefly, reverse transcription-PCR (RT-PCR) products of XBP1 mRNA were obtained from total RNA extracted using primers 5 0 -cggtgcgc ggtgcgtagtctgga-3 0 (sense) and 5 0 -tgaggggctgagagg tgcttcct-3 0 (antisense). Because a 26-bp fragment containing an ApaLI site is spliced on activation of XBP1 mRNA, the RT-PCR products were digested with ApaLI to distinguish the active spliced form from the inactive unspliced form. Subsequent electrophoresis revealed the inactive form as two cleaved fragments and the active form as a noncleaved fragment.
Immunohistochemistry
The institutional review board (IRB) at the Jordan University of Science & Technology (JUST) approved the study procedure. Sections of normal and CRC tissues (5 lm thick) were cut from the formalin-fixed paraffin-embedded blocks, deparaffinized in xylene and rehydrated through graded decreasing concentrations of alcohol. Antigen retrieval was carried out in 0.01 M of sodium citrate buffer (pH 6.0) by microwave oven heating for 5 min, repeated three times. Rabbit antihuman GRP78 antibody (Monoclonal IgG; Epitomics, CA, USA) was added at a dilution of 1:500 in Tris buffer for 1 h at room temperature before detection of bound antibodies using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions with Cytotechnology (2016) 68:459-467 461 visualization using diaminobenzidene (Dako, Carpinteria, CA, USA, Cat.K3466). Sections were counterstained with Harris' haematoxylin. Negative controls were performed for each section by omission of the primary antibody but keeping all other conditions constant. Sections were scored blindly by two investigators using at least four random microscopic fields for each sample. The percentage of positive cells was estimated from 0 to 100 % and the intensity of immunoreactivity (intensity score) was judged on an arbitrary scale of 0-4?: no reactivity (0), weakly positive (1?), moderately positive (2?), strongly positive (3?) and very strongly positive (4?). The immunoreactivity score (IRS) was derived by multiplying the percentage of positive cells with intensity of reactivity divided by 10.
Statistical analysis
Data are expressed as mean ± SE. The statistical significance of intergroup differences in normally distributed continuous variables was determined using Student's t test. P values B0.05 were considered statistically significant. P values\0.05 and\0.001 are indicated by * and **, respectively.
Results
The expression of GRP78 was characterized in CRC tissues by immunohistochemistry. Representative results are illustrated for normal colon tissues (Fig. 1a) in comparison with for CRC tissues (Fig. 1b-f ). As shown, the majority of histological sections of CRC tissues displayed enhanced immunohistochemical staining for GRP78. The immunoreactivity score (IRS) was higher in metastatic and poorly differentiated tissue samples compared to those in normal colon tissue (P = 0.001).
To explore the role of UPR in resistance of CRC cancer cells to chemotherapy-induced apoptosis, the expression levels of the GRP78 protein and the spliced XBP1 mRNA in a panel of CRC cell lines were examined, which are two commonly used indicators of UPR activation. GRP78 was expressed at varying, but higher levels in different cell lines relative to cultured normal fibroblasts (Fig. 2a) . Similarly, the spliced XBP1 was observed in all cultured cells except normal fibroblasts and HCT116 (Fig. 2b) . Results shown in Fig. 2c revealed that CRC cell lines express varying degrees of the UPR transducer IRE1a and ATF6. Expression of IRE1a was higher in HCT116 and Colo205 compared to SW620 and was barely detected in SW480. Appearance of the active form of ATF6 was detected in all cell lines but to different extents being the highest in SW480 and SW620 and to a lesser extent in HCT116 and Colo205. In all cell lines, there was an increase in the phosphorylated form of eIF2 that mediates inhibition of protein translation. In addition, levels of PERK were differentially expressed among different cell lines where high levels of p-PERK and PERK are expressed in SW620.
Next, the potential of different chemotherapeutic agents to induce apoptosis in CRC cells was studied. Cells were treated with cisplatin (166.7 lM), and 5-FU (50 lM). Apoptotic cells were measured using the propidium iodide method and flow cytometry. Results shown in Fig. 3 indicate that chemotherapeutic agents have different potentials to induce apoptosis among , and SW620 CRC cell lines were subjected to Western blotting analysis of ATF6, active ATF6, eiF2a, p-eiF2a, IRE1a, PERK, and p-PERK protein expression. Western blotting analysis of GAPDH levels was included to show that equivalent amounts of protein were loaded in each lane. Data are representative of two individual experiments Fig. 3 Chemotherapy-induced apoptosis in a panel of CRC cell lines. Cells were either untreated or treated with cisplatin (166.7 lM) or 5-FU (50 lM) for 72 h. Thereafter, apoptosis was measured by the propidium iodide method using flow cytometry. Bars indicate mean of three individual experiments ± SE Fig. 4 Correlation of the ratio of GRP78 relative expression and the levels of chemotherapy-induced apoptosis in a panel of CRC cell lines. The relative expression of GRP78 was determined by dividing the densitometric values of the protein by those of the GAPDH control. The intensity of the bands was quantified with the Bio-Rad VersaDoc TM image system. Regression analyses were carried out in a Macintosh computer using the StatView software Fig. 5 Inhibition of GRP78 expression by siRNA significantly enhanced chemotherapy-induced apoptosis. a Down-regulation of GRP78 expression in SW620 cells using siRNA. Cells were transfected with either a non-targeting (control) siRNA or with a GRP78 specific siRNA sequence at 50 or 100 nM for 24 h. The whole cell lysates (30 lg) were subjected to Western blot analyses. Data are representative of two individual experiments. b Effect of 5-FU and cisplatin treatment on levels of GRP78. Transfected cells with non-targeting siRNA or with GRP78 specific siRNA were treated with either 5-FU or cisplatin for 24 h. The whole cell lysates (30 lg) were subjected to Western blot analyses. Data are representative of two individual experiments. c Non-target (control) siRNA-transfected, and GRP78 siRNA-transfected CRC cells were treated with cisplatin (166.7 lM), and 5-FU (50 lM) for 72 h. Thereafter, apoptotic cells were measured using propidium iodide method in flow cytometry. Columns are mean of three individual experiments; bars, SE different CRC cell lines. For example, about 25 % of HCT116 cells underwent apoptosis by treatment with 5-FU and about 44 % underwent apoptosis by treatment with cisplatin.
In view of the above results we examined whether the expression of GRP78 in CRC cells might be associated with chemotherapy-induced apoptosis. Results in Fig. 4 show an inverse correlation between chemotherapy-induced apoptosis and expression of GRP78 in different CRC cell lines including Colo205, SW480, SW620, and HCT116 revealing that pretreatment evaluation of GRP78 levels might be indicative of CRC patient's response to either 5-FU or cisplatin.
We next examined the role of the basal activity of GRP78 in regulating sensitivity of CRC cells to chemotherapeutic drugs. As shown in Fig. 5a , siRNA knockdown of GRP78 inhibited its expression by 78 % (at 50 nM) and 85 % (at 100 nM) in SW620 cells, which is the least sensitive cell line, compared to cells transfected with the control siRNA. Figure 5b shows that inhibition of GRP78 expression markedly inhibited chemotherapy-induced GRP78 activation in all cell lines. Consistent with the importance of GRP78 in protection of cancer cells from ER stress-induced apoptosis (Rutkowski et al. 2006; Rutkowski and Kaufman 2007) , siRNA knockdown of GRP78 resulted in significant increases in the levels of apoptosis induced by chemotherapeutic agents (Fig. 5c) . These results suggest that GRP78 could be a potential target for therapeutic interventions, in particular, in combination with the DNA-damaging agents.
Discussion
Resistance of human CRC cells to the available chemotherapeutic agents is considered a major obstacle for the successful treatment. The UPR is believed to play a major role in the resistance of CRC to the available treatment modalities. Thus, development of effective approaches for the treatment of CRC requires the identification of the mechanisms employed in resistance of CRC cells against chemotherapy-induced apoptosis. Results presented in this study suggest an important role for GRP78 in mediating resistance of CRC to cisplatin and 5-FU. Given the highly malignant nature of CRC, it is conceivable that the rapid growth rate and perhaps inadequate vascularization would create a microenvironment with hypoxia, glucose deprivation, and acidosis, which in turn results in ER stress. In support of this, increased lactate dehydrogenase (LDH) levels, indicative of increased glycolytic activity, appear to be common in metastatic CRC (Maurel et al. 2007 ). A second mechanism by which GRP78 could promote resistance to chemotherapeutic agents is via its activation of signaling pathways by acting as a cell surface coreceptor. A study by Zhang et al. (2013) showed that breast and prostate cancer cells resistance to chemotherapy is associated with relocalization of GRP78 to the cell surface, binding of GRP78 to PI3 K and activation of PI(3,4,5)P3 production (Zhang et al. 2013) .
Our results were consistent with previous studies showing that the ER chaperone GRP78 expression contributes to in vitro and in vivo antiapoptotic effects and chemotherapy resistance in many cancers (Booth et al. 2012; Chang et al. 2012; Hardy et al. 2012; Jin et al. 2012; Lee 2007) . For example, levels of GRP78 in human gastric cancer cells are strongly correlated with taxane-based therapeutic resistance and recurrence of the disease (Yang et al. 2014) . Elevation of GRP78 has been shown to mediate resistance of the MCF-7 breast cancer cell line to radiation (Li et al. 2013 ) and oesophageal adenocarcinomas to neoadjuvant chemotherapy (Slotta-Huspenina et al. 2013 ). In addition, overexpression of GRP78 in several cancer cell lines promoted resistance to photodynamic therapy (Firczuk et al. 2013) and resulted in chemoresistance against etoposide and camptothecin by inhibiting apoptosis (Reddy et al. 2003) . Moreover, downregulation of GRP78 has been shown to induce apoptosis in colorectal carcinoma (Xing et al. 2011) , abrogate chemoresistance of hypopharyngeal carcinoma cells to cisplatin (Pi et al. 2014) , and reverse cisplatin resistance in human ovarian cancer (Fan et al. 2013) . In vivo, knockout of GRP78 in prostate epithelium inhibited prostate cancer development in mice (Fu et al. 2008 ). In the GRP78 heterozygous mice, tumor growth was significantly reduced (Dong et al. 2008) . Results presented in this study extend previous findings to include CRC cells and suggest a major role for GRP78 in mediating resistance of cancer cells to chemotherapeutic agents. Targeting of GRP78 can significantly overcome such resistance. Cytotechnology (2016) 68:459-467 465 Conclusions Results in the current study indicate that GPR78 exerts an important role in regulating CRC cell proliferation and apoptotic cell death. Targeting GRP78 may suppress therapeutic resistance in CRC cancer cells and might offer a novel strategy to treatment of CRC.
